Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:MESO NASDAQ:NBTX NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$12.82-3.0%$10.97$0.88▼$17.25$512.80M1.05436,563 shs30,468 shsMESOMesoblast$15.37-4.4%$14.93$12.66▼$21.50$1.99B2.08233,426 shs75,179 shsNBTXNanobiotix$40.32+1.9%$38.58$6.09▼$57.14$2.04B0.7869,424 shs39,237 shsURGNUrogen Pharma$41.56-2.2%$33.61$15.86▼$43.93$2.03B1.56788,826 shs88,132 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-0.30%+16.48%+24.72%-10.68%+799.32%MESOMesoblast-1.35%-9.97%+4.55%+3.68%-0.06%NBTXNanobiotix-2.06%+5.38%+8.06%+17.78%+578.97%URGNUrogen Pharma+1.05%+6.25%+20.91%+76.28%+127.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$12.82-3.0%$10.97$0.88▼$17.25$512.80M1.05436,563 shs30,468 shsMESOMesoblast$15.37-4.4%$14.93$12.66▼$21.50$1.99B2.08233,426 shs75,179 shsNBTXNanobiotix$40.32+1.9%$38.58$6.09▼$57.14$2.04B0.7869,424 shs39,237 shsURGNUrogen Pharma$41.56-2.2%$33.61$15.86▼$43.93$2.03B1.56788,826 shs88,132 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-0.30%+16.48%+24.72%-10.68%+799.32%MESOMesoblast-1.35%-9.97%+4.55%+3.68%-0.06%NBTXNanobiotix-2.06%+5.38%+8.06%+17.78%+578.97%URGNUrogen Pharma+1.05%+6.25%+20.91%+76.28%+127.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.67Moderate Buy$24.2589.16% UpsideMESOMesoblast 2.50Moderate BuyN/AN/ANBTXNanobiotix 2.50Moderate Buy$37.33-7.41% DownsideURGNUrogen Pharma 2.80Moderate Buy$41.630.15% UpsideCurrent Analyst Ratings BreakdownLatest ANL, MESO, URGN, and NBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026URGNUrogen Pharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $42.007/17/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026NBTXNanobiotix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026URGNUrogen Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $50.007/15/2026URGNUrogen Pharma The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$44.007/14/2026ANLAdlai Nortye Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/9/2026URGNUrogen Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/22/2026ANLAdlai Nortye Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/4/2026NBTXNanobiotix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$37.00 ➝ $46.00(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M102.56N/AN/A($0.21) per share-61.05MESOMesoblast$17.20M115.65N/AN/A$4.67 per share3.29NBTXNanobiotix$36.87M55.36N/AN/A($1.97) per share-20.47URGNUrogen Pharma$109.79M18.44N/AN/A($2.25) per share-18.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)MESOMesoblast-$102.14M-$0.28N/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)NBTXNanobiotix-$27.11MN/AN/A403.20N/AN/AN/AN/A9/30/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A25.66N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest ANL, MESO, URGN, and NBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ANLAdlai Nortye-$0.1333N/AN/AN/A$3.95 millionN/A8/6/2026Q2 2026URGNUrogen Pharma-$0.28N/AN/AN/A$63.55 millionN/A5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65MESOMesoblast0.101.581.41NBTXNanobiotixN/A1.091.09URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%MESOMesoblast1.43%NBTXNanobiotix38.81%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AMESOMesoblast18.80%NBTXNanobiotix3.45%URGNUrogen Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableMESOMesoblast80129.46 million105.12 millionOptionableNBTXNanobiotix10050.62 million48.87 millionNot OptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableANL, MESO, URGN, and NBTX HeadlinesRecent News About These CompaniesUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Here's What HappenedJuly 21 at 4:19 AM | marketbeat.comUroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow MoatJuly 20, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)July 17, 2026 | theglobeandmail.comShort sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027July 17, 2026 | msn.comUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ...July 15, 2026 | caledonianrecord.comCUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103July 15, 2026 | globenewswire.comUrogen Pharma (NASDAQ:URGN) Reaches New 52-Week High - What's Next?July 15, 2026 | marketbeat.comUroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% RunJuly 12, 2026 | fool.comUrogen Pharma (NASDAQ:URGN) Insider Sells 10,000 SharesJuly 11, 2026 | insidertrades.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesJuly 10, 2026 | marketbeat.comUroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerJuly 8, 2026 | globenewswire.comUrogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?July 7, 2026 | zacks.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?June 30, 2026 | fool.comMark Schoenberg Sells 10,000 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 25, 2026 | insidertrades.comUroGen Shareholders Approve Governance, Compensation and Auditor ChangesJune 23, 2026 | tipranks.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?June 14, 2026 | fool.comGuggenheim Remains a Buy on Urogen Pharma (URGN)June 10, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comMark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 10, 2026 | insidertrades.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comUroGen settles with Teva over Jelmyto patent disputeJune 3, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 20263 Top Financial Institutions Announce Over $70 Billion in Share RepurchasesBy Leo Miller | June 30, 2026Buyback Boom: These 3 Companies Are Betting Billions on Their Own StocksBy Jessica Mitacek | July 20, 2026Has Broadcom Become Too Expensive for Its AI Story?By Sam Quirke | July 17, 20265 Dividend Kings to Buy in July with Irresistible Value and YieldBy Thomas Hughes | July 8, 2026ANL, MESO, URGN, and NBTX Company DescriptionsAdlai Nortye NASDAQ:ANL$12.82 -0.40 (-3.03%) As of 11:31 AM Eastern This is a fair market value price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Mesoblast NASDAQ:MESO$15.36 -0.72 (-4.45%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Nanobiotix NASDAQ:NBTX$40.32 +0.77 (+1.95%) As of 11:31 AM Eastern This is a fair market value price provided by Massive. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Urogen Pharma NASDAQ:URGN$41.56 -0.94 (-2.20%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction Otis Took Another Guidance Cut—But the Story Isn't Over Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
